Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

被引：28
|
作者：
Berghmans, Thierry [1 ]
Dingemans, Anne-Marie [2 ,3 ]
Hendriks, Lizza E. L. [2 ]
Cadranel, Jacques [4 ,5 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Thorac Oncol Clin, Brussels, Belgium
[2] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol, Dept Pulm Dis GROW, Maastricht, Netherlands
[3] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands
[4] Hop Tenon, AP HP, Serv Pneumol, Paris, France
[5] Sorbonne Univ, Paris, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 55卷 / 02期
关键词：
IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.1183/13993003.01907-2019
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer
    Rais, Taruba
    Shakeel, Amna
    Naseem, Laiba
    Nasser, Nathalie
    Aamir, Minahil
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (12): : 7265 - 7269
  • [32] POOR PERFORMANCE STATUS NEGATIVELY AFFECTS SURVIVAL BENEFIT OF IMMUNOTHERAPY IN NONSMALL CELL LUNG CANCER
    Kawsar, Hameem
    Gaudel, Pramod
    Suleiman, Nahid
    Al-Jumayli, Mohammed
    Huang, Chao
    Neupane, Prakash
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A131 - A132
  • [33] Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
    Elena María Brozos-Vázquez
    Roberto Díaz-Peña
    Jorge García-González
    Luis León-Mateos
    Patricia Mondelo-Macía
    María Peña-Chilet
    Rafael López-López
    Cancer Immunology, Immunotherapy, 2021, 70 : 1177 - 1188
  • [34] Association between duration of immunotherapy and overall survival in advanced nonsmall-cell lung cancer
    Sun, Lova
    Bleiberg, Benjamin Aaron
    Hwang, Wei-Ting
    Marmarelis, Melina Elpi
    Langer, Corey J.
    Singh, Aditi Puri
    Cohen, Roger B.
    Mamtani, Ronac
    Aggarwal, Charu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
    Maria Brozos-Vazquez, Elena
    Diaz-Pena, Roberto
    Garcia-Gonzalez, Jorge
    Leon-Mateos, Luis
    Mondelo-Macia, Patricia
    Pena-Chilet, Maria
    Lopez-Lopez, Rafael
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (05) : 1177 - 1188
  • [36] Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
    Jia, Xiao-hui
    Xu, Hong
    Geng, Lu-ying
    Jiao, Min
    Wang, Wen-juan
    Jiang, Li-li
    Guo, Hui
    LUNG CANCER, 2020, 147 : 143 - 153
  • [37] Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
    Zienolddiny, Shanbeh
    Skaug, Vidar
    LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 1 - 14
  • [38] Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
    Kumar, S.
    Guleria, R.
    Singh, V.
    Bharti, A. C.
    Mohan, A.
    Das, B. C.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (04) : 885 - 892
  • [39] Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer
    Hu, Yanni
    Tian, Mei
    Zhang, Hong
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
  • [40] CON - THERAPEUTIC EMPIRICISM - THE CASE AGAINST CHEMOTHERAPY IN NONSMALL CELL LUNG-CANCER
    DOUGLAS, IS
    WHITE, SR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (05) : 1288 - 1291
12345